Amgen Replaces Two Top Executives, Beats Quarterly Estimates
- Harper, Hooper leaving; Bristol-Myers’s Gordon coming on board
- Biotech company is seeking to replace its fading blockbusters
Photographer: Tomohiro Ohsumi/Bloomberg
This article is for subscribers only.
Amgen Inc. shook up its C-suite on Thursday with two major changes as the biotechnology company searches for new therapies to replace fading blockbusters facing strong competition.
The executive moves were announced at the same time the drugmaker reported second-quarter results that beat analysts’ estimates. The Thousand Oaks, California-based company also raised its full-year guidance for revenue and profit.